Takeda Belgium soon will introduce treatments against solid tumors such as lung cancer. Lung cancer is the leading cause of cancer death worldwide. In 2012, 1.8 million new cases were diagnosed worldwide. In 2015, Belgium counted 5.711 patients with lung cancer (www.kankerregister.org).
Non-small cell lung cancer (NSCLC) is the most common type, affecting 85 % of lung cancer patients. Approximately 2-8 % of them have a rearrangement in a gene called anaplastic lymphoma kinase (ALK) which produces an abnormal ALK protein that causes the cells to grow and spread.
Takeda Oncology aspires to cure cancer by applying our commitment to science, to breakthrough innovation and to passion for improving patient care for people living with cancer around the world. Along with the global and local oncology communities, we make great strides in our fight against cancer. Our portfolio of paradigm-changing therapies combined with a dynamic, growing pipeline of investigational products have the potential to significantly improve patient outcomes across a number of types of cancer.